Cargando…

Efficacy of Brexpiprazole as Adjunctive Treatment in Major Depressive Disorder With Irritability: Post Hoc Analysis of 2 Pivotal Clinical Studies

Detalles Bibliográficos
Autores principales:	Fava, Maurizio, Weiller, Emmanuelle, Zhang, Peter, Weiss, Catherine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	Letters to the Editors - Research Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325249/ https://www.ncbi.nlm.nih.gov/pubmed/28195853 http://dx.doi.org/10.1097/JCP.0000000000000678

Ejemplares similares

Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies
por: Thase, Michael E, et al.
Publicado: (2018)

PS152. Efficacy and safety of brexpiprazole (OPC-34712) as adjunctive treatment in major depressive disorder: Meta-analysis of two pivotal studies
por: Eriksson, Hans, et al.
Publicado: (2016)

Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study
por: Davis, Lori L., et al.
Publicado: (2016)

Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning
por: Fava, Maurizio, et al.
Publicado: (2016)

PS151. Adjunctive brexpiprazole (OPC-34712) in patients with major depressive disorder and anxiety symptoms: an exploratory study
por: Davis, Lori, et al.
Publicado: (2016)

PM421. Efficacy and safety of brexpiprazole (OPC-34712) in acute schizophrenia: a pooled analysis of two pivotal studies
por: Skuban, Aleksandar, et al.
Publicado: (2016)

Effects of adjunctive brexpiprazole on calmness and life engagement in major depressive disorder: post hoc analysis of patient-reported outcomes from clinical trial exit interviews
por: Weiss, Catherine, et al.
Publicado: (2021)

The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies
por: Weiss, Catherine, et al.
Publicado: (2018)

Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies
por: Weiller, Emmanuelle, et al.
Publicado: (2017)

PS155. Long-term safety of adjunctive brexpiprazole (OPC-34712) in MDD: results from two 52-week open-label studies
por: Nelson, Craig, et al.
Publicado: (2016)

Spotlight on brexpiprazole and its potential in the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression
por: Bruijnzeel, Dawn, et al.
Publicado: (2016)

Efficacy and safety of brexpiprazole in patients with schizophrenia presenting with severe symptoms: Post-hoc analysis of short- and long-term studies
por: Meade, Nicole, et al.
Publicado: (2020)

Adjunctive Brexpiprazole and Functioning in Major Depressive Disorder: A Pooled Analysis of Six Randomized Studies Using the Sheehan Disability Scale
por: Hobart, Mary, et al.
Publicado: (2018)

M191. EFFECT OF BREXPIPRAZOLE ON ENGAGEMENT IN PATIENTS WITH SCHIZOPHRENIA: POST-HOC ANALYSIS OF THREE STUDIES
por: Ismail, Zahinoor, et al.
Publicado: (2020)

Real-World Economic Outcomes of Brexpiprazole and Extended-Release Quetiapine Adjunctive Use in Major Depressive Disorder
por: Seetasith, Arpamas, et al.
Publicado: (2019)

Effects of Brexpiprazole Across Symptom Domains in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies
por: Marder, Stephen R, et al.
Publicado: (2021)

PM385. Long-term safety of brexpiprazole (OPC-34712) in schizophrenia: results from two 52-week open-label studies
por: Correll, Christoph U., et al.
Publicado: (2016)

Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open‐label, long‐term safety and tolerability study
por: Lepola, Ulla, et al.
Publicado: (2018)

The effect of brexpiprazole in adult outpatients with early-episode schizophrenia: an exploratory study
por: Malla, Ashok, et al.
Publicado: (2016)

PS156. Adjunctive brexpiprazole, a novel effective strategy for treating Major depressive disorder?: Systematic review and Meta-analysis
por: Yoon, Seoyoung, et al.
Publicado: (2016)

A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder
por: Hobart, Mary, et al.
Publicado: (2019)

Real-World Determinants of Adjunctive Antipsychotic Prescribing for Patients with Major Depressive Disorder and Inadequate Response to Antidepressants: A Case Review Study
por: McIntyre, Roger S., et al.
Publicado: (2015)

Clinical role of brexpiprazole in depression and schizophrenia
por: Parikh, Nishant B, et al.
Publicado: (2017)

Effects of adjunctive brexpiprazole on sleep-wake and circadian parameters in youth with depressive disorders: study protocol for a clinical trial
por: Carpenter, Joanne S, et al.
Publicado: (2022)

Brexpiprazole as Adjunctive Treatment for Major Depressive Disorder Following Treatment Failure With at Least One Antidepressant in the Current Episode: a Systematic Review and Meta-Analysis
por: Kishi, Taro, et al.
Publicado: (2019)

Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study
por: Fleischhacker, W. Wolfgang, et al.
Publicado: (2016)

Brexpiprazole: A review of a new treatment option for schizophrenia and major depressive disorder
por: Diefenderfer, Lauren A., et al.
Publicado: (2018)

Understanding the emotions of patients with inadequate response to antidepressant treatments: results of an international online survey in patients with major depressive disorder
por: Mago, Rajnish, et al.
Publicado: (2018)

Suicidality and symptoms of anxiety, irritability, and agitation in patients experiencing manic episodes with depressive symptoms: a naturalistic study
por: Eberhard, Jonas, et al.
Publicado: (2016)

Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial
por: Fava, Maurizio, et al.
Publicado: (2018)

Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post‐hoc analysis of a long‐term open‐label study
por: Ishigooka, Jun, et al.
Publicado: (2021)

Post‐hoc analysis investigating the safety and efficacy of brexpiprazole in Japanese patients with schizophrenia who were switched from other antipsychotics in a long‐term study (Secondary Publication)
por: Ishigooka, Jun, et al.
Publicado: (2020)

Effect of Brexpiprazole on Prolactin and Sexual Functioning: An Analysis of Short- and Long-Term Study Data in Major Depressive Disorder
por: Clayton, Anita H., et al.
Publicado: (2020)

The Importance of Irritability as a Symptom of Major Depressive Disorder: Results from the National Comorbidity Survey Replication
por: Fava, Maurizio, et al.
Publicado: (2009)

Impressive Response with Brexpiprazole in Ekbom’s syndrome
por: Hsiao, J., et al.
Publicado: (2022)

Anxiety, irritability, and agitation as indicators of bipolar mania with depressive symptoms: a post hoc analysis of two clinical trials
por: Suppes, Trisha, et al.
Publicado: (2017)

Post hoc tests in analysis of variance
por: Mahajan, Anjali
Publicado: (2016)

Efficacy and tolerability of brexpiprazole in patients with psychotic and mood disorders: a pilot study
por: Civardi, S.C., et al.
Publicado: (2022)

Efficacy of physical activity in the adjunctive treatment of major depressive disorders: preliminary results
por: Pilu, Alessandra, et al.
Publicado: (2007)

Evaluating the efficacy of vilazodone in achieving remission in patients with major depressive disorder: post-hoc analyses of a phase IV trial
por: Citrome, Leslie, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qjonqshhukvpjmqt7pj4884f73